Operational Benchmarks for Psychedelic Care

December 2025’s studies add practical detail to a shift already underway: psychedelic care is moving from “can it work” to “how do we deliver it safely, consistently, and in a way payers can cover.”

Economic, Clinical, and Real-world Insights

The latest research on psychedelic-assisted therapies in August provides critical insights into economic feasibility, implementation models, and clinical effectiveness across diverse patient groups.

Cross-Diagnostic Potential of Psychedelics

New psychedelic studies highlight cross-indication applicability of MDMA-assisted therapy, risks with naturalistic use, and potential life-extending effects of psilocybin.